Premium content from Motley Fool Share Advisor UK
Our monthly Fire Best Buys Now are designed to highlight our team’s three favourite, most timely Buys from our growing list of growth-focused Fire recommendations, to help Fools build out their portfolios.
“Best Buys Now” Pick #1:
Haleon (LSE:HLN)
- Since being spun off from GSK, Haleon has performed about as well as anyone could have hoped.
- The consumer health group has been growing sales at a steady clip thanks to full control over R&D and marketing budgets, reducing leverage thanks to increased cash flow, and conducting M&A to rid itself of lower growth brands and bulk up in attractive areas.
- If Haleon can continue growing sales from its ‘Power Brands’ like Sensodyne, Advil, and Theraflu at 5%+ rates then achieving the medium-term target of consistent 4%-6% organic growth is very achievable. Pair that with ongoing margin improvements and reduction in interest payments and you have a recipe for a group that’ll have plenty of cash to either spend on M&A or return to shareholders through its dividend and share repurchase programmes.
- Those financial considerations and the defensive nature of the consumer health market means we think Haleon is worth considering in January at its current valuation of circa 20 times forward earnings.
“Best Buys Now” Pick #2:
Redacted
Want All 3 “Best Buys Now” Picks? Enter Your Email Address!
Should you invest £1,000 in Gsk right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?
